Back to catalogue
BiologicalCancer & Oncology
HEBERSaVax®
Cuban biotech oncology product under investigation for cancer immunotherapy.
Product information
HEBERSaVax — a Cuban biotech oncology product developed by CIGB.
Indications
Investigational cancer immunotherapy.
Formulation
Investigational biologic.
Administration
As per clinical trial protocols.
Precautions
Investigational product — available only through authorized clinical programs.
Product information
- Manufacturer
- CIGB, Havana
- Regulatory status
- Investigational / registered in Cuba
Cancer & Oncology
CIMAvax-EGF®
Therapeutic vaccine targeting the EGF pathway for non-small cell lung cancer — registered in multiple countries.
VAXIRA® (Racotumomab)
Monoclonal antibody vaccine targeting NeuGcGM3 ganglioside antigens expressed on lung tumors.
HeberFERON®
Combined interferon therapy for severe psoriasis and chronic hepatitis.